MK-677 Research for Bone Density
An evidence-based overview of research examining MK-677 in the context of bone density. This page synthesizes findings from peer-reviewed literature.
Research Summary
Clinical trials evaluated MK-677 for bone density in elderly populations. The sustained increase in GH and IGF-1 stimulates bone turnover markers. A 2-year study in elderly women showed increased bone mineral density at multiple sites. The drug increases osteoblast activity markers and may benefit osteoporosis. Long-term safety data is limited, and MK-677 was not approved for osteoporosis. Concerns about glucose tolerance may limit use in elderly patients.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Bone Density
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. MK-677 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.